William Blair analyst Ryan Daniels has reiterated their bullish stance on EHC stock, giving a Buy rating today.
Ryan Daniels has given his Buy rating due to a combination of factors including Encompass Health’s strong financial performance and promising future outlook. The company reported impressive first-quarter results for 2025, surpassing revenue and earnings expectations. This was driven by a healthy mix of volume growth and increased revenue per discharge, alongside effective expense management that resulted in strong operating leverage.
Additionally, the management’s decision to raise guidance for the year reflects confidence in sustained top-line growth and stable expense trends. Daniels views Encompass as a resilient player in the healthcare sector, with limited exposure to macroeconomic risks such as potential Medicaid cuts. This stability, coupled with the company’s ability to navigate a challenging operating environment, supports the Buy rating as Encompass is poised for continued financial success.
According to TipRanks, Daniels is a 4-star analyst with an average return of 6.8% and a 46.79% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Health Catalyst, Encompass Health, and HealthStream.
In another report released today, Raymond James also reiterated a Buy rating on the stock with a $120.00 price target.